Amelia Carro Hevia’s Post

TRIPLE THREAT AKA RETATRUTIDE: A novel glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors agonist. MASLD is a leading cause of liver transplant especially in women and those over the age of 65. As an obesity medicine doctor whose practice is housed in a transplant department, I too often see the consequences of MASLD and obesity. MASLD is a metabolic disease whose treatment requires a comprehensive approach. Given the rising rates of type 2 diabetes and obesity, two of the most significant risk factors for MASLD, we desperately need effective treatments to improve health outcomes. In 2023, a phase 2 study was published evaluating the percentage change from baseline weight in people with obesity on retatrutide. The study found that treatment with the 12-mg dose of retatrutide resulted in a mean weight reduction of 24.2% after 48 weeks! A sub study of retatrutide published today evaluated the change from baseline in liver fat in people with MASLD and obesity. At week 48 of treatment at the highest dose of retatrutide (12 mg), a whopping 93% of participants achieved a liver fat content of less than 5% (more than 5% is considered significant and a diagnosis of MASLD) with a 25.9% reduction in body weight. Reductions in liver fat were strongly associated with reductions in body weight, abdominal subcutaneous adipose tissue (fat that is more superficially located in the central abdomen) and visceral adipose tissue (fat that sits inside of or closest to the internal organs in the abdomen), and with improvements in markers of insulin sensitivity and lipid metabolism. Mark my words because this is just the beginning of what will be the explosion of cardiometabolic medications in the next decade. It is an INCREDIBLY exciting time to practice cardiometabolic medicine and I really cannot wait to see what the future holds!! Source: https://lnkd.in/gEjiWMTE #Transplant #Obesity #Weightloss #Liverdisease #Cardiometabolic

Deeping into adiposity features from the so called 'athlete's paradox' 1️⃣ Skeletal myocyte fat storage in ahtletes 👉🏻 The muscle is a main actor in the continuum of chronic non-communicable disorders (atherosclerosis, cancer, cognitive disorders, parkinson's disease, obesity, inflammation, diabetes, autoinmune diseases). 👉🏻 Storage of fat, glycogen and other substances is one of its main functions. 👉🏻 Intramyocellular lipid metabolism plays an important part of cardio-kidney-hepato-metabolic spectrum 2️⃣ ❓Is muscle fat storage different in athletes and sedentary/diabetes people? 3️⃣ ❓Could exercise interventions modulate lipid metabolism/fat distribution/insulin sensitivity? The present study aims to solve these questions and might answer some of the common dilemas on current management of obesity, diabetes, cardiovascular disorders and other disturbances. Exercise is an utmost when dealing with such metabolic/inflammatory deviations Synergistic effects with current and future drugs are the key to a better understanding and prognosis. Did you know about muscle effects of other drugs? Semaglutide, tirzepatide, Azelaprag, Liraglutide, BGE-105/GLP-1, Orforglipron, Retatrutide, Survodutide https://lnkd.in/dazipemK #exerciseismedicine #obesity #cardioX #meded #inflammation #lipiddisorders #hipercolesterolemiafamiliar #diabetesmellitus #apelina #apelin #cardiorenometabolico #cardiokidneymetabolic #NASH #masdl #steatohepatitis

Final countdown for the European Atherosclerosis Society Congress What can we expect from this year's programme? Don't miss any topic and plan your sessions. Have a look at this one (May 28th; 13:30-14:30) ✍ 3-YEAR CLINICAL OUTCOMES OF PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK ELIGIBLE FOR PCSK9 INHIBITOR TREATMENT ✍ BEMPEDOIC ACID AND CARDIOVASCULAR DISEASE OUTCOMES IN PATIENTS WITH OBESITY: A CLEAR OUTCOMES SUBSET ANALYSIS ✍ A COMPREHENSIVE ANALYSIS OF WOMEN'S PARTICIPATION IN CARDIOVASCULAR TRIALS ✍ MEDITERRANEAN DIET REDUCES ATHEROSCLEROSIS PROGRESSION THROUGH THE MODULATION OF ADVANCED GLYCATION END PRODUCTS METABOLISM: FROM THE CORDIOPREV STUDY ✍ BEMPEDOIC ACID EFFICACY AND SAFETY IN 7,597 NON-DIABETIC PATIENTS, WITH AND WITHOUT METABOLIC SYNDROME, FROM THE RANDOMIZED, PLACEBO-CONTROLLED CLEAR OUTCOMES TRIAL ✍ PCSK9 INHIBITOR PREFERENCES AND EXPERIENCES OF PATIENTS AND HEALTHCARE PROFESSIONALS IN DECISION MAKING: A MIXED-METHODS STUDY ✍ OPTIMIZING AND TAILORING LIFESTYLE ADVICE FOR WOMEN WITH A HISTORY OF PRE-ECLAMPSIA: INSIGHTS FROM PATIENTS AND HEALTHCARE PROFESSIONALS Are you going to miss it? Plan your congress here https://lnkd.in/eKV2FUqc #bempedoicacid #alirocumab #evolocumab #inclisiran #PCSK9i #womensincardiology #HFA2024 #heartfailure2024 #obesity #STEPHF #semaglutide #mediterraneandiet #lifestyle #lyfestylemedicine #integrativemedicine #integrativecardiology #medicinaintegrativa #cardiologiaintegrativa #acidobempedoico #ethylicosapent #pelacarsen #olpasiran #Muvalaplin #Lerodalcibep #Evinacumab #omega3 #icosapentodeetilo #IPE #acidoeicosapentanoico Clara Bonanad Lozano Anny A. Romero Secin International Lipid Expert Panel (ILEP) National Lipid Association Société Québécoise de Lipidologie, de Nutrition et de Métabolisme Alberto Cordero Leopoldo Perez de Isla Marco Puma Duque Estibaliz Jarauta Meritxell Royuela Juncadella Teresa Arrobas Velilla Lorenzo Facila SERGIO HEVIA NAVA Maria Riestra #FHFoundation #elitetrainer #LBCT #lipidpanel #tryglicerides #reduceit

A limited analysis substudy of SURMOUNT-1 indicates that tirzepatide improves blood pressure in obesity-related hypertension. Strengths: 24 hour ambulatory BP monitoring was used. Limitations: BP was only recorded at baseline and 1 other time https://lnkd.in/gBEnPVHp

EVERYONE IS TALKING ABOUT ATHLETES ON THESE 'OLYMPIC DAYS' So let's deep into adiposity features from the so called 'ATHLETES' PARADOX' 1️⃣ Skeletal myocyte fat storage in ahtletes 👉🏻 The muscle is a main actor in the continuum of chronic non-communicable disorders (atherosclerosis, cancer, cognitive disorders, parkinson's disease, obesity, inflammation, diabetes, autoinmune diseases). 👉🏻 Storage of fat, glycogen and other substances is one of its main functions. 👉🏻 Intramyocellular lipid metabolism plays an important part of cardio-kidney-hepato-metabolic spectrum 2️⃣ ❓Is muscle fat storage different in athletes and sedentary/diabetes people? 3️⃣ ❓Could exercise interventions modulate lipid metabolism/fat distribution/insulin sensitivity? The present study aims to solve these questions and might answer some of the common dilemas on current management of obesity, diabetes, cardiovascular disorders and other disturbances. Exercise is an utmost when dealing with such metabolic/inflammatory deviations Synergistic effects with current and future drugs are the key to a better understanding and prognosis. Did you know about muscle effects of other drugs? Semaglutide, tirzepatide, Azelaprag, Liraglutide, BGE-105/GLP-1, Orforglipron, Retatrutide, Survodutide https://lnkd.in/dazipemK #exerciseismedicine #obesity #cardioX #meded #inflammation #lipiddisorders #hipercolesterolemiafamiliar #diabetesmellitus #apelina #apelin #cardiorenometabolico #cardiokidneymetabolic #NASH #masdl #steatohepatitis

https://lnkd.in/gbwd-Bxk Article title: Alcoholism, Fibroblast Growth Factor 23 and Cardiovascular Risk   Author(s): Emilio González-Reimers; Geraldine Quintero-Platt; Candelaria Martín-González; Lucía Romero-Acevedo; Daniel Martínez-Martínez; Melchor Rodríguez-Gaspar; Francisco Santolaria-Fernández   Journal: Archives of Clinical Hypertension   Journal ISSN: 2640-771X Abstract: Background: Bone metabolism is tightly regulated by several hormones that are synthesized in bone cells and that have effects not only on bone but on several distant organs. These hormones are involved in intermediate metabolism and modulate fatty acid transport, playing a role in insulin resistance, liver steatosis, atherosclerosis and cardiovascular risk. Aims: We review the association of fibroblast growth factor-23 (FGF-23) and α-Klotho with cardiovascular risk, especially in the alcoholic patient. #Hypertension #CardiovascularRisk #Bone #FGF23 #Alcoholism #VascularCalcification #AlphaKlotho #ArterialBloodPressure #ArterialHypertension #BloodPressureMonitoring #BloodPressureVariability #CardiovascularRisks #CentralBloodPressure #HighBloodPressure #HypertensionDuringPregnancy #HypertensionInChildren #HypertensionInNewborn #HypertensionManagement #HypertensionNeonate #HypertensionNursing #HypertensionNutrition #HypertensionRiskFactors #HypertensionTreatment #Peertechz #PeertechzPublications #HypertensiveCrisis #HypertensiveEmergency #IdiopathicIntracranialHypertension #InducedHypertension #IntracranialHypertension #LowBloodPressure #PersistentPulmonaryHypertension #PortalHypertension #ProtopulmonaryHypertension #PulmonaryHypertension #RenalDisorders #TraumaticIntracranialHypertension

#breakingNews -Does dual GLP1/GIP tirzepatide/ #Mounjaro 🔽 cardiovascular risk like semaglutide/#ozempic? At least for preserved ejection fraction heart failure - looks like YES in this RCT. it’s been important to prove tirzepatide has similar benefits as semaglutide since it’s not simply an analog but a combination of two hormones ((GLP1 of semaglutide) and GIP. #obesity #heartFailure #AskDrBob #zepbound https://lnkd.in/gxWf6R2Z

Impaired awareness of #hypoglycemia (#IAH), the inability to detect the onset of hypoglycemia, is a serious consequence of long-term #T1D. IAH is associated with higher risk of asymptomatic and severe hypoglycemia and a lower quality of life. Signaling and metabolic pathways involved in the counter-regulatory response to hypoglycaemia are currently not well-understood, but are suggested to result in adaptive changes in the brain, leading to IAH. In this publication, co-authored by Henk-Jan Aanstoot and Dick Mul of Diabeter, #metabolomics and genome-wide association (#GWA) methodologies were combined to look for metabolites that are expressed differentially between people with type 1 diabetes (PWDs) with IAH and PWDs without IAH. A number of metabolites were identified that showed higher expression in PWDs with IAH.   Please look here for more information: https://lnkd.in/eqcxXCXd   #diabetes #diabetesresearch #type1diabetes #diabetescompications #type1diabetescomplications #hypocompass #impairedawareness 

Hypertension is a condition characterized by consistently high pressure of blood against the walls of the arteries, which can lead to severe complications such as heart disease, stroke, and kidney problems.💓 Fortunately, there are various therapies and solutions available to manage hypertension effectively. Lifestyle modifications play a crucial role, including adopting a low-sodium diet, engaging in regular exercise, maintaining a healthy weight, and managing stress levels.🩺 In addition to lifestyle changes, medications are often prescribed to control blood pressure. These may include diuretics, beta-blockers, ACE inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, and others, tailored to individual needs.⚕️ By implementing a combination of lifestyle adjustments and appropriate medical treatments, individuals can effectively manage hypertension and reduce the risk of associated complications. As a CRO specialized in cardiovascular diseases, we support trials aimed at advancing the understanding and treatment of conditions like hypertension. _______________________________________________________________ ⁉️ Are you looking for excellence in a CRO Contact us! 📞💻 _______________________________________________________________ Leading clinical trials with detail, efficiency, and excellence ♾️Share if others could benefit from this too! 🔔 To follow Hemex click the bell on the profile.